Membrane encapsulated nanoparticles and method of use
Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the inventive nanoparticles are also provided. Further provided are immunogenic compositions comprising the inventive nanoparticles, and methods of using the inventive immunogenic compositions for eliciting an immune response, and for treating or preventing diseases or condition, such as neoplasm or cancer, or disease or conditions associated with cell membrane inserting toxin. Vaccines comprising the immunogenic composition comprising the nanoparticles are also provided.
1. An RBC membrane coated nanoparticle comprising:
a) a polymeric inner core comprising a non-cellular material; and
b) an outer surface comprising a plasma membrane derived from a red blood cell,
wherein said inner core supports said outer surface, said RBC membrane coated nanoparticle lacks at least 50% hemoglobin of said red blood cell from which said plasma membrane is derived, said RBC membrane coated nanoparticle has a core-shell structure and said RBC membrane coated nanoparticle has a half-life in blood circulation in vivo for about 2-5 times of the half-life of a PEG-coated nanoparticle, and
wherein said RBC membrane coated nanoparticle and said PEG-coated nanoparticle have the same polymeric inner core and shape, and said RBC membrane coated nanoparticle and said PEG-coated nanoparticle have diameters in all three dimensions from about 50 nm to about 250 nm, and
wherein said RBC membrane coated nanoparticle does not comprise a releasable cargo that comprises a bioactive agent, and
wherein said inner core has a shape of sphere, square, rectangle, triangle, circular disc, cube-like shape, cube, rectangular cuboid, cone, cylinder, prism, pyramid, or right-angled circular cylinder.
2. The nanoparticle of claim 1 , wherein the non-cellular material in the inner core comprises a material selected from the group consisting of poly(lactic-coglycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.
3. The nanoparticle of claim 1 , wherein the nanoparticle has a half life in blood circulation in vivo for about 5 to about 40 hours.
4. A medicament delivery system, which comprises an effective amount of the nanoparticle of claim 1 , wherein the nanoparticle is the sole bioactive agent in the system.
5. A pharmaceutical composition comprising an effective amount of the nanoparticle of claim 1 and a pharmaceutically acceptable carrier or excipient.
6. The nanoparticle of claim 1 , wherein the inner core has a shape of square, rectangle, triangle, circular disc, cone, prism, or right-angled circular cylinder.
7. The nanoparticle of claim 1 , which has a diameter from about 50 nm to about 150 nm.
8. The nanoparticle of claim 1 , which lacks at least 80% hemoglobin of the red blood cell from which said plasma membrane is derived.
9. The nanoparticle of claim 1 , which has a diameter from about 50 nm to about 150 nm and wherein the non-cellular material in the inner core comprises poly(lactic-co-glycolic acid) (PLGA).
10. The nanoparticle of claim 9 , wherein the nanoparticle is configured to reduce hemolytic activity of a-toxin.
11. The nanoparticle of claim 1 , wherein the outer surface further comprises a synthetic membrane.
12. The nanoparticle of claim 1 , wherein the outer surface further comprises added cholesterol, free fatty acid, and/or phospholipid.
13. The nanoparticle of claim 1 , wherein the inner core has a shape of sphere.